Saturday, January 30, 2010 1:44:40 AM
Recent ANIX News
- Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs • PR Newswire (US) • 04/06/2026 01:10:00 PM
- Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing • PR Newswire (US) • 04/01/2026 12:50:00 PM
- Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer • PR Newswire (US) • 03/30/2026 01:05:00 PM
- Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast • PR Newswire (US) • 03/12/2026 02:38:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/09/2026 08:16:07 PM
- Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology • PR Newswire (US) • 03/09/2026 12:30:00 PM
- Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress • PR Newswire (US) • 03/02/2026 02:10:00 PM
- Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat • PR Newswire (US) • 02/23/2026 01:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 01:02:40 PM
- Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation • PR Newswire (US) • 02/09/2026 01:00:00 PM
- Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization • PR Newswire (US) • 02/02/2026 02:00:00 PM
- Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology • PR Newswire (US) • 01/27/2026 01:30:00 PM
- Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic • PR Newswire (US) • 12/15/2025 01:45:00 PM
- Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants • PR Newswire (US) • 12/11/2025 11:02:00 PM
- Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025 • PR Newswire (US) • 12/10/2025 02:00:00 PM
- Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization • PR Newswire (US) • 11/17/2025 01:15:00 PM
- Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s • PR Newswire (US) • 11/12/2025 02:00:00 PM
- Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025 • PR Newswire (US) • 11/10/2025 03:30:00 PM
- Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic • PR Newswire (US) • 11/05/2025 01:55:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2025 01:13:33 PM
- Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference • PR Newswire (US) • 10/23/2025 12:45:00 PM
- Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology • PR Newswire (US) • 10/20/2025 12:25:00 PM
- Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 • PR Newswire (US) • 10/08/2025 03:01:00 PM
